Member Info for Barnacle

What's going on with the trades today???

Looks like QVH are gearing up for Bleepa...

Main duties of the job

Community Diagnostic Pathway Coordinator

An exciting opportunity has arisen to recruit a Pathway Coordinator to work within the Community Diagnostic Centre (CDC) at QVH. This role will be a key point of contact and coordination for all CDC patients under the care the breathlessness pathway and individualised diagnostic tests.

This important role will need to work closely with the QVH respiratory, cardiology and Imaging services along with clinicians, managers and other Trust staff to ensure the trust is following diagnostic pathways effectively and that patients progress through their pathway with minimal delay.

The successful candidate should have experience of working in healthcare, a good understanding of diagnostic waiting times and be willing to embrace the challenges of ensuring patients are following the optimal pathway during their care.

This has already overtaken Mortal Shell revenues, now stating $4.3M revenue for Balatro, against $3.8M revenue for Mortal Shell. Quite incredible really, and an unexpected hit for Playstack I'm guessing.

The partnership that Feedback has with Qure.ai is also worth noting, both for opportunities in India and the UK. From September 2021:

“We are delighted to be working with Qure.ai; …this is only the beginning to forging a pathway for a new global regime of diagnostic testing and screening. The combination of Qure.ai’s AI reporting capabilities through Bleepa’s instant and secure communications platform has the potential to provide timely, efficient and cost-effective care across a number of clinical settings.

“We are particularly excited to be working on screening for TB and to help deliver this to even the remotest of locations. We have the potential here to build true access to healthcare for all in India. Although we are looking at India initially, Qure.ai are a great partner and their technologies hold just as much benefit here in the UK and we are excited to explore a number of opportunities for the technologies within the NHS and UK private market. ”

“We are delighted to be working with Qure.ai; …this is only the beginning to forging a pathway for a new global regime of diagnostic testing and screening. The combination of Qure.ai’s AI reporting capabilities through Bleepa’s instant and secure communications platform has the potential to provide timely, efficient and cost-effective care across a number of clinical settings.

“We are particularly excited to be working on screening for TB and to help deliver this to even the remotest of locations. We have the potential here to build true access to healthcare for all in India. Although we are looking at India initially, Qure.ai are a great partner and their technologies hold just as much benefit here in the UK and we are excited to explore a number of opportunities for the technologies within the NHS and UK private market. ”

FEEDBACK WINS IHW GOLD AWARD - SUPPORTING TB SCREENING PROGRAMMES IN RURAL COMMUNITIES, Jan 2024

Bleepa uses local mobile networks to securely push X-rays, acquired in rural settings, to a dedicated cloud environment where they can be processed by AI to assist interpretation. Specialists can review the images using Bleepa’s in-app clinical grade image viewer and chat directly with the care team in the rural setting to reach the correct management plan for the patient, supported by the AI-generated report.

Bleepa connects with Qure.ai’s AI platform so the images can be processed and interpreted, returning the results within a matter of minutes. This helps the radiologist to triage the scan and flag any abnormalities which would indicate a TB diagnosis.

Since the start of the project in March 2022 nearly 2,000 patients have been screened at the hospital, with 19.6% of scans coming back as indicating positive for signs of TB.

Continued.....

Moving forward into 2023/24

• QVH is also involved in national pilot work on the skin pathway, sharing best practice and learning with other CDCs.

• From April 2023 the abdominal pathway will provide differential diagnosis around another common set of symptoms.

• Expansion and further development of patient clinical pathways including chronic cough and headache.

• Electronic key performance indicator monitoring through the digital platform, this will enable performance to be monitored closely, ensuring the best outcome for patients.

• Improve wider pathways and access to management and onward referral for patients without having to go back through primary care for this referral process.

• From April 2023 tests available for GPs to order will also include 24 hour blood pressure and 24 hour ECG monitoring

• The number of GP practices which QVH works with will be increased.

• Over the next two years QVH will receive national investment to support both workforce and treatment space. There are national workforce challenges in regarding to imaging and diagnostic expertise, so QVH workforce plans include apprenticeships and other routes to developing skilled staff. There will be a phased recruitment approach to meet the anticipated growth in demand as the service is extended to cover more GP surgery catchments and additional tests.

• The CDC currently operates out of pre-existing QVH clinical space but plans are developing for a new dedicated building

Very interesting reading, Bleepa an integral part of the QVH digital Pathways. Page 40/41

https://www.qvh.nhs.uk/wp-content/uploads/2023/06/QVH-Quality-Report-2022-3.pdf

NHS Community diagnostic centres (CDCs) provide a broad range of elective diagnostics (including checks, scans and tests) away from acute facilities, so reducing pressure on hospitals, providing quicker access to tests and greater convenience to patients. The improved access provided by the CDCs supports reducing unwarranted variation in referral,

access and associated health inequalities. The QVH CDC was established to start delivering digitally connected diagnostic capacity for the local population. The service provides, in as few visits as possible, coordinated diagnostic tests enabling fast diagnosis on a range of a clinical pathways to improve experience and outcomes.

A working group of clinicians co-chaired by the National Clinical Directors for Respiratory and Heart Disease and finalised in November 2021 developed a breathlessness pre-diagnosis pathway. The pathway was developed in response to the common presentation of breathlessness in primary care and associated delays in treatment and avoidable hospital

admissions. The pathway includes an asynchronous multidisciplinary (MDT) approach to support the clinical decision making and patient treatment.

The team at Queen Victoria Hospital Community Diagnostic Centre have been piloting the pathway through the CDC outpatient setting, with the aim of delivering on the objectives of increasing diagnostic capacity, improving productivity and efficiency, delivering a more personalised diagnostic experience, supporting integration of care, improving staff

development and satisfaction and making every contact count. The aim of the pathway is not to monitor known diagnoses that have deteriorated but to focus on speeding up new diagnoses.

QVH has been recognised nationally for this innovative work on the ‘breathlessness pathway’. This work has been presented nationally and regionally at the request of Sir Mike Richards and the NHS England CDC development team

QVH is currently working with eight local General Practitioner (GP) practices. GPs in these practices are able to refer their patients for breathlessness pathway and physiological tests including spirometry, FeNO (measuring exhaled nitrous oxide, a biomarker for asthma) and electrocardiogram (ECG).

Nick Meyhew reposted this post from the NCA, I suspect that they would be using Bleepa for this:

"Our colleagues at the #RoyalOldham have been part of an innovative pilot looking to transform services for children and young people living with asthma and related conditions.

The project takes a whole-household approach to asthma intervention identifying children and young people admitted to hospital with asthma or respiratory illnesses, who smoke or live in a household that smokes."

Ricky Barber, Chidren's Unit Manager explains more....

You can watch the full video

https://orlo.uk/rSGzS

Net Revenue now $2.5M after 7 days......

Hi CC, not sure what you mean by 'free' test programmes, all the NHS pilots have created revenue, and not been offered at a discount. The pilots are needed to create the necessary evidence to enable decisions to be made within the NHS. There has to be proof that Bleepa will actually cut waiting times and save money, which we know it does. These two further pilots are going to further prove that Bleepa/Carelocker can be rolled out to other CDCs and the results from QVH replicated. Positive results will lead to Bleepa being rolled out nationally I believe.

Https://gamesensor.info/news/balatro_sales_first_three_days_steam

Since its launch on Steam on February 20, 2024, Balatro has taken the gaming community by storm, with astounding sales figures. According to GameSensor's forecast, Balatro sales raked in nearly $2 million within its first three days on the platform, a testament to its widespread appeal. What's more, Balatro has sold close to 100,000 copies during this brief period on Steam, solidifying its position as a top contender in the casual strategy genre.

Balatro's meteoric rise isn't just confined to its sales figures; the game has garnered praise from both players and critics alike. Boasting a stellar 5-star rating on Steam and an impressive 8.6 points out of 10 on Metacritic, Balatro has struck a chord with gamers worldwide. Critics have hailed its innovative gameplay mechanics, awarding it an impressive 88 points out of 100 possible, further cementing its status as a must-play title.

At its core, Balatro is a hypnotically addictive deathmatcher that seamlessly blends the thrill of illegal poker with the excitement of roguelike elements. Players are thrust into a high-stakes world where they must uncover game-changing jokers, unleash adrenaline-inducing combos, and outwit their opponents to emerge victorious. With each playthrough offering a fresh and exhilarating experience, Balatro promises endless hours of entertainment for players of all skill levels.

Whether you're a PC enthusiast or prefer gaming on consoles, Balatro has you covered. In addition to its availability on PC via Steam, the game is also playable on Nintendo Switch, PlayStation 4, PlayStation 5, Xbox One, and Xbox Series X/S consoles, ensuring that players can dive into the action no matter their preferred platform.

With its diverse player base spanning the globe, Balatro has transcended language barriers to become a true international sensation. While English-speaking players comprise the majority at almost 65%, the game's popularity extends to Chinese and French-speaking audiences as well. It's worth noting that while Balatro on Steam currently supports only English, its universal appeal knows no bounds.

Hi Dibs, it is looking encouraging with the awards in India. I suspect that like the NHS, Indian Healthcare budgets will be allocated in the new financial year, so April could be a very busy month on the news front, fingers crossed....

Net Revenue for Balatro is already $2M in just one week......

Feedback Medical's innovative secure clinical communications platform Bleepa has the potential to revolutionise healthcare communication practices in India, aligning with the Digital Personal Data Protection Act 2023 hashtag#dpdpact

Recognizing the game-changing potential of this technology and the forward-thinking leadership driving its adoption, HEAL Health has honoured our India Managing Director, Rohit Singh, with the prestigious Next Gen Healthcare Changemaker Award under 45. This accolade was presented at the 8th Health Writers and Influencers Convention in AIIMS, New Delhi on February 21st, cementing our commitment to transforming healthcare communication in India. 🏆

Contracts near term..........

Agreed Madpad, I've just invested an initial amount in to Trufin based on the release of Balataro. It's generating significant income, and has only been out for a week, incredible....!

Seems to be a Director and shareholder of a Business Finance Company; Apollo Business Finance Limited.

Good to see Mr Cranston increasing his holding.

Up to 3.41%.

Very encouraging!

You're so right IB, these two pilots, which as you say have been funded by NHS England, are undoubtedly a stepping stone to a further roll out across other Community Diagnostic Centres. If proven successful, then it should accelerate Bleepas adoption by other CDCs and provide the evidence needed for NHS decision makers....

"The evidence generated by these pilots will build the case for subsequent funding of a pathway approach to CDC delivery in subsequent financial years and NHSE will be closely monitoring the pilot outcome data as the programme rolls out in order to inform forward planning."

"We are very confident that this will be in the short term."

Sounds like it will be similar to the NHS where customers will initially request pilots, which will be paid for, before entering in to a contract.

With regard to the Awards that Bleepa has been winning in India, the judging panel often consists of senior people within the large Hospital Chains. This has the added benefit of making them very aware of the product, so makes a good sales opportunity as well as marketing opportunity.

Peak buying activity for the NHS is during March and April so with that in mind;

There is the QVH tender which is due at the end of March. £1.6M over two years.

There are also the two pilots running at Amersham CDC in Buckinghamshire and a pan regional pilot across Buckinghamshire, Oxfordshire and Berkshire ICS (BOB ICS), which are due to complete at the end of March. These could lead on to contracts or further paid pilots.

Using Bleepa as a WhatsApp replacement should gain sales traction from April onwards when new budgets become available.

Royal Berkshire NHS; contract renewal and talk of expanding the scope of Bleepa to emulate a WhatsApp replacement, which should lead to further revenue

Northern Care Alliance; contract renewal, scope for rolling out across greater Manchester......?

Https://www.voxmarkets.co.uk/articles/feedback-plc-ceo-dr-tom-oakley-on-how-digital-diagnostics-can-help-solve-the-nhs-waiting-list-crisis-f5e6ccc/